Watch out, watch out, the FDA are about

被引：28

作者：

Cano, Stefan J. ^{[1
]}

Hobart, Jeremy C.

机构：

[1] Peninsula Coll Med & Dent, Neurol Outcome Measures Unit, Plymouth, Devon, England

来源：

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY | 2008年 / 50卷 / 06期

关键词：

D O I：

10.1111/j.1469-8749.2008.00408.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

[No abstract available]

引用

页码：408 / 409

页数：2

共 10 条

[1] Evidence-based guidelines for using the short form 36 in cervical dystonia [J].

Cano, Stefan J. ;

Thompson, Alan J. ;

Bhatia, Khailash ;

Fitzpatrick, Ray ;

Warner, Thomas T. ;

Hobart, Jeremy C. .

MOVEMENT DISORDERS, 2007, 22 (01) :122-126

[2]

European European Medicines Agency, 2006, REFL PAP REG GUID US

[3]

Food and Drug Administration, PAT REP OUTC MEAS US

[4]

Hagell P, 2008, J NEUROL, V255, P246, DOI 10.1007/s00415-008-0708-y

[5] The SF-36 in multiple sclerosis: why basic assumptions must be tested [J].

Hobart, J ;

Freeman, J ;

Lamping, D ;

Fitzpatrick, R ;

Thompson, A .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 (03) :363-370

[6] Quality of life measurement after stroke - Uses and abuses of the SF-36 [J].

Hobart, JC ;

Williams, LS ;

Moran, K ;

Thompson, AJ .

STROKE, 2002, 33 (05) :1348-1356

[7] Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations [J].

Hobart, Jeremy C. ;

Cano, Stefan J. ;

Zajicek, John P. ;

Thompson, Alan J. .

LANCET NEUROLOGY, 2007, 6 (12) :1094-1105

[8] Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions [J].

Jenkinson, C ;

Hobart, J ;

Chandola, T ;

Fitzpatrick, R ;

Peto, V ;

Swash, M .

JOURNAL OF NEUROLOGY, 2002, 249 (02) :178-183

[9] FDA draft guidance and health-outcomes research [J].

Revicki, Dennis A. .

LANCET, 2007, 369 (9561) :540-542

[10]

Ware J.E., 2003, SF 36 HLTH SURVEY MA

← 1 →